Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI reveals how weight loss drugs reshape organs in severely obese teens

NCT ID NCT07702825

Disease control Sponsor: Alder Hey Children's NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study uses MRI scans to measure how weight loss treatments affect fat in the liver, pancreas, and other organs of adolescents aged 12 to 18 with severe obesity. Researchers compare two approaches: GLP-1 receptor agonist drugs combined with lifestyle changes versus lifestyle changes alone. Participants undergo MRI scans at the start and after 9 months to track changes in organ fat and body composition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
GLP-1 receptor agonists (a class of weight-loss drugs) plus lifestyle changes
What this could lead to
If successful, this could show that combining GLP-1 drugs with lifestyle changes improves organ health in teens with severe obesity, pointing toward better treatment strategies.
What could go wrong
This is a small, early-stage study with only 30 participants, so results may not apply to all teens. The MRI scans may not detect meaningful changes, and the drugs can cause side effects like nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible adolescents under the care of the tertiary weight management service (Complications from Excess Weight service) at Alder Hey Children's hospital will be offered to enrol in the study once a decision has been taken whether or not they are being started on GLP1 receptor agonist treatment.

Ages

12 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 12 to \<18 years at the time of enrolment * BMI \>99.6th centile or \>2.67 SDS * Informed consent from parent(s) (or person with parental responsibility) and assent from the child or young person for participants aged less than 16 years (or) * Informed consent from the participant if aged ≥ 16 years. Exclusion Criteria: * Body weight above upper limit of the scanner (\>250 kilograms) * Needs general anaesthesia for the MRI scanning * Any contraindications for MRI- Metal implants/claustrophobia * Previous use of GLP-1 receptor agonist * Refusal to consent or refusal to assent from a competent older adolescent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Childhood obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

morbid obesity Obesity obesity disorder Pediatric Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Childhood obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alder Hey Children's hospital

    RECRUITING

    Liverpool, Merseyside, L122AP, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.